1. < Home

subgroup analysis

Regorafenib use in patients with unresectable hepatocellular carcinoma: analyses of subgroups of special interest in the observational REFINE study

Kim YJ, Merle P, Finn RS, Klümpen HJ, Lim HY, Ikeda M, Granito A, Masi G, Gerolami R, Pinter M, Babajanyan S, Twumasi-Ankrah P, Ghadessi[...]

By afschroeder • April 17, 2026
Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease

Curigliano G, Hu X, Dent R, Yonemori K, Barrios CH, Pierga JY, Puglisi F, Ferrero JM, Jung KH, Bagegni NA, Collignon J, Gil-Gil M, Wu[...]

By afschroeder • March 5, 2026
Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN Study

Reinmuth N, Goldman JW, Chen Y, Hotta K, Trukhin D, Statsenko G, Hochmair M, Özgüroğlu M, Ji JH, Garassino MC, Poltoratskiy A, Verderame F, Havel[...]

By afschroeder • September 1, 2025
Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma

van der Heijden MS, Powles T, Gupta S, Loriot Y, Galsky MD, Valderrama BP, Sridhar SS, Yu EY, Iyer G, Kikuchi E, Castellano D, Hoffman-Censits[...]

By afschroeder • August 13, 2025
JPEN Journal Club 87. The subgroup paradox

Koretz RL. JPEN Journal Club 87. The subgroup paradox. JPEN J Parenter Enteral Nutr. 2024 Sep 7. doi: 10.1002/jpen.2684. Epub ahead of print. PMID: 39243214.

By sjmartinez • September 8, 2024